Heterocyclic amines having central nervous system activity
Patent 5436240 Issued on July 25, 1995. Estimated Expiration Date: 
October 6, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
October 6, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3200123 1,2,5,6-Tetrahydro-4H-pyrrolo(3,2,1-j)quinolin-2-ones 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole Benzoquinolizines as 2 -adrenoceptor antagonists Di/tetra-hydroquinolines 9H-pyrido[2,B-8]indole-3-carboxylic acid ester compounds having useful pharmaceutical activity 1,3,4,5-tetrahydrobenz(c,d)indoles Fused heteroalkylene quinolinamines Patent #: 5112830 InventorsAssigneeApplicationNo. 132633 filed on 10/06/1993US Classes:514/224.5, At least three cyclos in the polycyclo ring system514/228.2, Polycyclo ring system having the additional hetero ring as one of the cyclos514/230.2, Ring nitrogen shared by two of the cyclos514/233.2, Ring nitrogen shared by two of the cyclos514/250, At least three rings in the polycyclo ring system514/253.03, Tricyclo ring system having the additional six-membered nitrogen hetero ring as one of the cyclos544/60, Additional hetero ring containing544/101, Tricyclo ring system having the oxazine ring as one of the cyclos544/115, The diazine ring is one of the cyclos in a polycyclo ring system544/126, The additional six-membered hetero ring is one of the cyclos in a tricyclo ring system544/344, Tricyclo ring system having the diazine ring as one of the cyclos546/95Benzo(a)quinolizines (including hydrogenated)ExaminersPrimary: Shah, Mukund J.Assistant: Grumbling, Matthew V. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/50A61K 031/495 C07D 513/12 C07D 471/12 AbstractTricyclic nitrogen containing compounds, having central nervous system activity of the following structural formula: ##STR1## and pharmaceutically acceptable salts thereof wherein R1, R2, and R3 are independently hydrogen, C1-6 alkyl, alkenyl, or alkynyl, C3-10 cycloalkyl, or R1 and R2 are joined to form a C3-7 cyclic amine which can contain additional heteroatoms; X is hydrogen, C1-6 alkyl, halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl; A is SO2, N, CH, CH2, CHCH3, C=O, C=S, C-SCH3, C=NH, C-NH2, C-NHCH3, CNHCOOCH3, or C-NHCN. B is CH2, CH, C=O, N, NH or N-CH3 ; n is 0 or 1; and D is CH, CH2, C=O, 0, N, NH or N-CH3. These new compounds are suitable for treating schizophrenia, Parkinson's disease, anxiety, depression or as compounds for lowering blood pressure in animal or human hosts.Other References
Field of SearchAt least three cyclos in the polycyclo ring systemPolycyclo ring system having the additional hetero ring as one of the cyclos Ring nitrogen shared by two of the cyclos Ring nitrogen shared by two of the cyclos At least three rings in the polycyclo ring system Benzo(a)quinolizines (including hydrogenated) Additional hetero ring containing Tricyclo ring system having the oxazine ring as one of the cyclos The diazine ring is one of the cyclos in a polycyclo ring system The additional six-membered hetero ring is one of the cyclos in a tricyclo ring system Tricyclo ring system having the diazine ring as one of the cyclos |
| ||||||||||||||
